Search results for: 'Complex Drug'

09 Sep 2024  |  Global  |  Technology Research

AI-based Drug Repurposing Market, Growth Opportunities, Global, 2024-2029

AI-based Drug Repurposing is emerging as a new and faster approach to bringing drugs to patients.

Infographics

×

This study analyzes the emergence of AI-based drug repurposing and examines the factors driving and hindering adoption. The limitation of traditional drug discovery has led to the growing interest in AI -based drug repurposing, which offers numerous advantages in terms of time, speed, and cost. AI-based drug repurposing has been explored across dif...

Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy. They suffer from off-target effects, poor bioavailability, low solubility, systemic toxicity, and poor permeability. While the small molecule drug development pipeline remains a leading therapeutic class, it is essen...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

Globally, diagnosis of metabolic diseases such as type 2 diabetes and obesity have increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with hea...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprise innovation insights across antibody and cellular therapies. The study also encompasses recent innovations in liquid biopsy tests, drug delivery and drug discovery platforms.The Life Science, Health & Wellness TOE will feature disruptive technology advan...

22 Aug 2024  |  Global  |  Technology Research

Pipeline Assessment for Cardiovascular Diseases

Advanced Drug Modalities Fuel Cardiovascular Therapeutics Future Growth Potential

Infographics

×

Globally, CVD is the leading cause of death, with resurgence in higher-income countries and higher prevalence in low- and middle-income countries. While there have been many advancements made to this indication using wearables and advanced diagnostics and devices, growth in therapeutics has been veiled. Traditional pharmacotherapy faces the drawbac...

This edition of the Oil and Gas (O&G) TOE features information about the conversion of natural gas into high-quality liquid derivatives using gas-to-liquid (GTL) technology. The TOE also covers the innovations in drone technology for monitoring midstream and upstream assets. The TOE focuses on real-time data management technologies to enhance drill...

This analysis provides an overview and advancements in the oral solid dosage formulation industry, including an evaluation of the current industry scenario, competitive landscape, and regulatory landscape. The scope of the analysis is global, focusing on North America (NA), Europe, Asia-Pacific (APAC), the Middle East, and Latin America (LATAM). It...